ASRS 2024: Real-world safety and efficacy of aflibercept 8 mg in the treatment nAMD
Image courtesy: Ophthalmology Times
Listen to Deepak Sambhara, MD, present the findings from a real-world case study that measured the safety and efficacy of Aflibercept 8 mg for treating nonexudative AMD at ASRS 2024. Dr. Sambhara states that patients who were switched to aflibercept 8 mg showed improvements both in visual acuity and anatomically as indexed by OCT (SPECTRALIS, Heidelberg Engineering) with greater durability.
For more valuable information about our products, educational offerings, learning materials and events
Subscribe to our Newsletter orContact us
